Why low-cost ketamine is still inaccessible to many with severe depression
A case study on ketamine reveals systemic barriers that prevent repurposing existing low-cost drugs like ketamine for treatment-resistant depression.
Oct 23, 2023
0
0
A case study on ketamine reveals systemic barriers that prevent repurposing existing low-cost drugs like ketamine for treatment-resistant depression.
Oct 23, 2023
0
0
The public sector should pay if EU demands efficient removal of pharmaceuticals from wastewaters, according to researchers at the Center for Antibiotic Research, CARe, at the University of Gothenburg. Their argumentation ...
Sep 5, 2023
0
1
For patients with immunoglobulin A (IgA) nephropathy, nine months of treatment with targeted-release formulation of budesonide (Nefecon) yields a greater reduction in estimated glomerular filtration rate (eGFR) than placebo, ...
Aug 22, 2023
0
1
Various medical circumstances, including heart attacks and extreme cases of COVID-19, necessitate the use of anticoagulants, medicines that prevent blood clots. But the most commonly used, heparin, can induce potentially ...
Aug 21, 2023
0
104
New cancer drugs are being launched rapidly before their long-term effectiveness for patients can be evaluated. Several years later, most of them still lack scientific evidence for increasing life expectancy or improving ...
Aug 15, 2023
0
7
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by multisystem involvement. Systemic sclerosis (SSc) or scleroderma is another rheumatic autoimmune disease that affects blood vessels, skin, ...
Aug 8, 2023
0
1
Globally, opioid prescribing has increased significantly over the past three decades. In 2019, Australia had the eighth highest level of opioid use in the world.
Aug 7, 2023
0
23
Researchers at the University of Colorado Anschutz Medical Campus have helped confirm the dosing, safety and effectiveness of a drug formulation designed for treating children with human immunodeficiency virus (HIV).
Aug 2, 2023
0
52
Voclosporin can preserve kidney function up to three years for patients with lupus nephritis, according to a study published online July 19 in Arthritis & Rheumatology.
Jul 26, 2023
0
4
Trial results of a new drug to treat Alzheimer's disease, donanemab, shows it can slow cognitive decline by 35%. The drug has been hailed as a "turning point" in Alzheimer's treatment.
Jul 19, 2023
0
7